Thaci D, Piaserico S, Warren RB, Gupta AK, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol 2021 Feb 5. doi: 10.1111/bjd.19866.
PMID: 33544883